Summit Therapeutics Inc. Number Of Share Options Forfeited In Share-based Payment Arrangement
Summit Therapeutics Inc. (SMMT) reported Number Of Share Options Forfeited In Share-based Payment Arrangement of 3.49 million shares for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Notes › Compensation Related Costs
ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement · last filed 2020-06-02
- Summit Therapeutics Inc. number of share options forfeited in share-based payment arrangement for the quarter ending 2020-03-31 was 3.49M shares, a 1598.88% increase year-over-year.
- Summit Therapeutics Inc. number of share options forfeited in share-based payment arrangement for the quarter ending 2019-10-31 was 237.64K shares, a 96.66% decline year-over-year.
- Summit Therapeutics Inc. number of share options forfeited in share-based payment arrangement for the quarter ending 2019-07-31 was 310.81K shares, a 89.49% decline year-over-year.
- Summit Therapeutics Inc. number of share options forfeited in share-based payment arrangement for the quarter ending 2019-04-30 was 205.41K shares, a 17.84% decline year-over-year.
| Period end | Number Of Share Options Forfeited In Share-based Payment Arrangement 3 month | Number Of Share Options Forfeited In Share-based Payment Arrangement 6 month | Number Of Share Options Forfeited In Share-based Payment Arrangement 9 month | Number Of Share Options Forfeited In Share-based Payment Arrangement 11 month | Number Of Share Options Forfeited In Share-based Payment Arrangement 12 month |
|---|---|---|---|---|---|
| 2020-03-31 | 3.49M shares 6-K · filed 2020-06-02 | ||||
| 2019-12-31 | 1.19M shares 20-F · filed 2020-04-30 | ||||
| 2019-10-31 | 237.64K shares derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | 548.45K shares derived: sum of 2 quarters · filed 2019-12-17 | 753.86K shares 6-K · filed 2019-12-17 | ||
| 2019-07-31 | 310.81K shares derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | 516.22K shares 6-K · filed 2019-10-11 | |||
| 2019-04-30 | 205.41K shares 6-K · filed 2019-06-12 | ||||
| 2019-03-31 | 145.44K shares 6-K · filed 2020-06-02 | ||||
| 2019-01-31 | 2.08M shares derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 9.19M shares derived: sum of 2 quarters · filed 2020-04-30 | 12.15M shares derived: sum of 3 quarters · filed 2020-04-30 | 12.40M shares 20-F · filed 2020-04-30 | |
| 2018-10-31 | 7.11M shares derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | 10.07M shares derived: sum of 2 quarters · filed 2019-12-17 | 10.32M shares 6-K · filed 2019-12-17 | 10.48M shares derived: sum of 4 quarters · filed 2019-12-17 | |
| 2018-07-31 | 2.96M shares derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | 3.21M shares 6-K · filed 2019-10-11 | 3.36M shares derived: sum of 3 quarters · filed 2019-10-11 | 3.41M shares derived: sum of 4 quarters · filed 2019-10-11 | |
| 2018-04-30 | 250.00K shares 6-K · filed 2019-06-12 | 406.79K shares derived: sum of 2 quarters · filed 2019-06-12 | 453.47K shares derived: sum of 3 quarters · filed 2019-06-12 | 1.58M shares derived: sum of 4 quarters · filed 2019-06-12 | |
| 2018-01-31 | 156.79K shares derived: 20-F 12 month − 6-K 9 month · filed 2019-03-29 | 203.47K shares derived: sum of 2 quarters · filed 2019-03-29 | 1.33M shares derived: sum of 3 quarters · filed 2019-03-29 | 1.43M shares 20-F · filed 2019-03-29 | |
| 2017-10-31 | 46.68K shares derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11 | 1.17M shares derived: sum of 2 quarters · filed 2018-12-11 | 1.27M shares 6-K · filed 2018-12-11 | ||
| 2017-07-31 | 1.13M shares derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20 | 1.23M shares 6-K · filed 2018-09-20 | |||
| 2017-04-30 | 100.00K shares 6-K · filed 2018-06-05 | ||||
| 2017-01-31 | 916.70K shares 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |